Spots Global Cancer Trial Database for Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer

Official Title: Phase II Study of Irinotecan (CPT 11) and Cisplatin (CDDP) in Metastatic or Locally Advanced Penile Carcinoma

Study ID: NCT00066391

Conditions

Penile Cancer

Interventions

cisplatin

irinotecan hydrochloride

neoadjuvant therapy

Study Description

Brief Summary: RATIONALE: Drugs used in chemotherapy such as irinotecan and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Combining irinotecan with cisplatin may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining irinotecan with cisplatin in treating patients who have locally advanced or metastatic penile cancer.

Detailed Description: OBJECTIVES: * Determine the anticancer activity of irinotecan and cisplatin in patients with locally advanced or metastatic penile cancer. * Determine the objective response rate and duration of response in patients treated with this regimen. * Determine the acute side effects of this regimen in these patients. OUTLINE: This is an open-label, nonrandomized, multicenter study. Patients receive irinotecan IV over 30 minutes on days 1, 8, and 15 and cisplatin IV over 1-3 hours on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients not undergoing local treatment receive up to 8 courses. Patients planning to undergo surgery receive up to 4 courses. Patients are followed every 8 weeks until disease progression and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 13-28 patients will be accrued for this study.